Varicose veins are a frequent cause of morbidity and, with the continual advancement of endovenous treatment modalities, standardised outcome measures have become important to better determine the relative effectiveness of each modality. To date, the focus for many investigators has been the prevention and monitoring of recurrent disease, but disease recurrence is a complicated subject matter in venous varicosity literature.
Recurrence rates following varicose vein intervention are arguably greater than would be acceptable in many other treated disease groups with recurrence rates of up to 47% reported five years after endovenous intervention. 1 In addition, the definition of recurrence is expansive. The recurrent varices after surgery guidelines developed in 1998 define recurrence as true recurrent varices as well as residual veins (untreated at first intervention) or the development of new varices resultant from disease progression.
2 Naturally, residual varices following initial treatment are different from truly recurrent varices and the inclusion of this category may complicate interventional outcomes. Furthermore, the type of recurrence is largely dependent on the treatment modality used. Neovascularisation is more likely to occur following surgical stripping and venous recanalisation following endovenous ablation. Evidence, so far, points to overall recurrence rates being similar between surgical stripping and endovenous ablation. 1 Another issue is the degree of heterogeneity in reporting standards in clinical trials that assess varicose vein interventions, both in terms of the type of outcomes reported and the follow-up periods at which these outcomes are assessed. 3, 4 An attempt to solve the problem has been made in a joint statement by the American Venous Forum and the Society of Interventional Radiology in their Recommended Reporting Standards for Endovenous Ablation. 5 In these guidelines, it is suggested that anatomic and imaging outcomes can be used as primary outcome measures for technology assessment studies -presumably because the sonographic identification of reflux, recanalisation or neovascularisation will correctly identify pathological recurrence or treatment failure regardless of symptomatology -but that these measures should not be used as outcomes for clinical studies. Yet, a large meta-analysis restricted outcome reporting to anatomical success. 6 Taking heed of this guidance draws attention to the difference between clinical and anatomical recurrence and the relationship between anatomical disease and symptomatology. Shepherd et al. 7 investigated the relationship between several clinical outcome measures and demonstrated that anatomical and haemodynamic measures correlate poorly with functional outcomes, though there was better correlation with quality of life measurements. Therefore, it may be prudent for treatment algorithms for recurrent disease to include symptomatic criteria as this will provide the basis for differentiating between those patients that require reintervention for recurrent disease and those that do not.
Furthermore, if parallels are drawn between primary and recurrent disease, it is known that the presence of less severe primary disease does not necessarily predispose one to develop more severe disease over time. 8 If the same is true for disease recurrence, offering treatment for asymptomatic recurrences would be unnecessary for some.
A recent study demonstrated that the probability of re-intervention at five years is similar for endovenous laser ablation (EVLA), radiofrequency ablation and surgery at 26-27%. 9 Ultrasound-guided foam sclerotherapy (UGFS) and conservative management carry greater risk with probabilities as high as 56% and 72%, respectively.
9
A meta-analysis of generic (EQ-5D) and disease-specific (Aberdeen Varicose Vein Questionnaire [AVVQ]) quality of life scores by the same group did not demonstrate statistically significant Academic Section of Vascular Surgery, Imperial College London, London, UK differences between any of the comparative groups six months after surgery. 9 The only significant difference found was between generic quality of life scores following UGFS and EVLA, whereby EVLA was shown to have a significantly better impact on quality of life at six weeks, but this difference became insignificant by six months post intervention. 9 Thus, if treatment modalities cannot be differentiated based on quality of life scores and the identification of anatomical recurrence alone is not recommended or clinically pertinent, then symptomatology that prompts re-intervention is left as the last remaining outcome measure that could potentially offer insight into inter-modality treatment efficacy. This, in turn, would help to determine which treatment modalities are most cost-effective.
Further research and expert panel discussions are required to consider whether re-intervention rates for symptomatic disease recurrence should be a required reporting standard in clinical studies. Doing so would place symptomatology centre stage, align outcome measure monitoring with common healthcare rationing criteria for primary disease and push for an expert consensus on the criteria required to offer patients reintervention.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: APC would like to acknowledge funding from Imperial Private Healthcare. RB would like to acknowledge funding from Vascular Insights, Inc.
Guarantor

AHD.
Contributorship
APC and RB contributed equally to the manuscript. AHD supervised the development of the manuscript. All authors reviewed and edited the manuscript and approved the final version.
